The recent Nasdaq entrant prepares to move AKY-2519 into the clinic.
ApexOnco Front Page
Recent articles
A Libtayo combo fails to beat Keytruda in first-line melanoma.
The company secures funding to push its lead candidate towards US approval.
Prexasertib data worsen again, and biomarkers are up in the air.
Readout of the Pivot-006 trial is brought forward by nearly a year.
$650m buys the group rights to RemeGen’s RC148.
A pivotal trial will test the KRAS G12D degrader setidegrasib plus chemo in first-line PDAC.
ELVN-001 is made to look more like Terns’ TERN-701.
